Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), provides comment on the Women?s Health Initiative (WHI) Coronary Artery Calcium Study published in The New England Journal of Medicine (NEJM).
The targeted use of an anti-estrogen drug could prolong the life of some ovarian cancer patients by up to three years, and delay the use of chemotherapy in others, revealed by researchers at the University of Edinburgh.
Researchers at the University of Edinburgh have shown that hormone therapy can extend life in ovarian cancer patients, giving women a new alternative to chemotherapy.
Low levels of testosterone may increase the long-term risk of death in men over 50 years old, according to researchers with the Department of Family and Preventive Medicine at the University of California, San Diego School of Medicine.
A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.
When Sociologist Rene Almeling decided to look into the operations of U.S. sperm banks and egg agencies, the UCLA Ph.D. candidate in sociology thought she knew what she would find.
Researchers from the University of Pennsylvania School of Medicine found in a database study of women heart patients that COX inhibitors such as traditional nonsteroidal anti-inflammatory drugs (NSAIDs) may undermine any purported protection against heart disease in participants taking estrogen therapy. The results were described this week in PLoS Medicine.
Scientists with the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have for the first time implicated a growth-promoting cellular protein as one trigger of the inevitable recurrence of advanced prostate cancer in men who are undergoing drug treatment to shut down their sex hormones, or androgens.
A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.
Scientists have discovered one of the reasons why bladder cancer is so much more prevalent in men than women: A molecular receptor or protein that is much more active in men than women plays a role in the development of the disease. The finding could open the door to new types of treatment with the disease.